NEW YORK, Sept. 3 /PRNewswire/ -- Concentric Pharma Advertising, one of the fastest growing marketing agencies in the healthcare field, has been named agency of record by Discovery Labs for SURFAXIN(R) (lucinactant), an investigational drug being reviewed by the Food and Drug Administration for the treatment of respiratory distress syndrome (RDS) in newborns.
"We selected Concentric for this assignment because the company's strategic insight and creative vision best captured the essence of the SURFAXIN brand," said John Wilson, vice president of sales and marketing at Discovery, adding that the agency's in-depth knowledge of neonatology and acute RDS in premature infants also played a significant part in the decision.
The full-service U.S. assignment will include a wide range of activities, including corporate and product branding, positioning, and the creation of support materials geared to neonatologists, neonatal intensive care unit (NICU) nurses, respiratory therapists, hospital pharmacists, and, potentially, parents of newborns. The agency's account team will be led by Ed Mutch, account supervisor. Blake Benner, director of marketing at Discovery Labs, will manage the account on the client side.
Discovery Labs, headquartered in Warrington, Pa., is a biotechnology company developing novel surfactant replacement therapies (SRTs) with potential for application across the continuum of respiratory diseases, initially focusing on RDS in premature infants.
Concentric Pharma Advertising, an independent healthcare advertising and marketing firm established in 2002, is one of the fastest growing agencies in the healthcare field, enjoying double-digit revenue growth for the fourth year in a row. In the past year alone, the agency won 10 new assignments, launched a new division, expanded its senior management team, and won several awards in prestigious U.S. and global ad competitions.
Concentric offers a wid
|SOURCE Concentric Pharma Advertising|
Copyright©2008 PR Newswire.
All rights reserved